Perspective: A Cancer Immunologist in a Molecular Imaging Lab
Navigating science is hard. Finding the right people to navigate it with you is harder still.
FBXW7/GSK3β-mediated proline-rich 11 degradation promotes oxidative DNA damage and inhibits tumor progression in renal cell carcinoma
RCC exhibits defects in homologous recombination and oxidative DNA damage. Our study shows that PRR11, upregulated in RCC, promotes proliferation and migration via AKT signaling. This activation inhibits GSK3β/FBXW7-mediated PRR11 degradation, forming a feedback loop that worsens RCC progression.
Computational mining the anticancer potential of non-oncology drugs
By building a machine learning model to combining knowledge of cancer genetics and network biology, we developed a personalized method to recommend FDA approved non-oncology drugs for cancer treatment.
Targeting Stem Cells in Medulloblastoma
Here, we tested the hypothesis that OLIG2, a key transcriptional regulator of neural development, plays a crucial role in maintaining cancer stem cells (CSC) in medulloblastoma tumors that can be exploited using a new type of targeted therapy.
Targeting Cell Fate Transitions in Medulloblastoma: Precision and Context Matter
Research from my lab led by Kinjal Desai, out today in Nature Communications, probes cell fate transitions in the medulloblastoma hierarchy. By blocking OLIG2, which drives the transition from quiescence to proliferation in the neoplastic stem cells, we block de novo tumour formation and regrowth.